Raymond James analyst Steven Seedhouse resumes coverage on Audentes Therapeutics (NASDAQ: BOLD) with an Outperform rating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE